Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.

Brain pathology (Zurich, Switzerland) - 1 Jan 2024

Wongsurawat Thidathip, Jenjaroenpun Piroon, Anekwiang Panatna, Arigul Tantip, Thongrattana Wichayapat, Jamshidi-Parsian Azemat, Boysen Gunnar, Suriyaphol Prapat, Suktitipat Bhoom, Srirabheebhat Prajak, Cheunsuchon Pornsuk, Tanboon Jantima, Nookaew Intawat, Sathornsumetee Sith

Abstract excerpt

The 2021 WHO Classification of Central Nervous System Tumors recommended evaluation of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion in addition to codeletion of 1p/19q to characterize IDH-mutant gliomas. Here, we demonstrated the use of a nanopore-based copy-number variation sequencing (nCNV-seq) approach to simultaneously identify deletions of CDKN2A/B and 1p/19q. The nCNV-seq approach was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 1

Share to Chromosomes, Human, Pair 19

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Nanopore Sequencing

Share to Oligodendroglioma

Source

Open in PubMed Open full text

Identifiers

PMID: 37574201
DOI: 10.1111/bpa.13203
PMCID: PMC10711254

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.PMID 37574201Read ↗

Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencingSemantic proximity Read ↗

Whole-Genome Long-Read Sequencing for Rapid Comprehensive Molecular Diagnostics of Brain TumorsSemantic proximity Read ↗

Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics.Semantic proximity Read ↗

Rapid-CNS<sup>2</sup>: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept studySemantic proximity Read ↗

Clinical impact of molecular profiling in rare brain tumors.Semantic proximity Read ↗

Detection of chromosome structural variation by targeted next-generation sequencing and a deep learning applicationSemantic proximity Read ↗

A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse gliomaSemantic proximity Read ↗

Diagnostic utility of genetic alterations in distinguishing IDH-wildtype glioblastoma from lower-grade gliomas: Insight from next-generation sequencing analysis of 479 cases.Semantic proximity Read ↗

Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Semantic proximity Read ↗

iSCORED: nanopore-based random genomic sampling for intraoperative molecular diagnosisSemantic proximity Read ↗

Diagnostic Utility of Oncomine Comprehensive Assay v3 in Differentiating Between Isocitrate Dehydrogenase (IDH)-mutated Grade II-III Astrocytoma and Oligodendroglioma.Semantic proximity Read ↗

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.